Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM12460A vs Insulin Glargine in T2DM
NCT03332836Phase 1Terminated
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised trial of HM12460A in type 2 diabetes mellitus (T2DM) (3 cohorts), sponsored by Hanmi Pharmaceutical. Primary endpoint: Number of participants with adverse events at 1 month. Started Oct 2017; status: terminated.
02
Drugs
HM12460A
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03332836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332836.